[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612230":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":34,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":10},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Acne vulgaris patients",null,"Both males and females aged 15-40 years.\n\n• Mild, Moderate, severe and very severe cases will be included",[13],"Other: Blood sample collection for biochemical analysis of serum ceramides (C16, C24) and sphingosine-1-phosphate (S1P).",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy controls","Healthy controls\n\nDescription:\n\nAge- and sex-matched healthy volunteers",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Blood sample collection for biochemical analysis of serum ceramides (C16, C24) and sphingosine-1-phosphate (S1P).","Venous blood samples (5 mL) will be collected from all participants under aseptic conditions. Serum will be separated and stored at -80°C until analysis. Quantitative estimation of ceramide C16, ceramide C24, and sphingosine-1-phosphate (S1P) will be performed using liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS). No therapeutic intervention will be given.",[9,15],{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dalia Ahmed Helmy Ahmed","Dermatology Resident At Albalyna central hospital","100612230","evaluation-of-serum-ceramides-c16-c24-and-sphingosine-1-phosphate-s1p-in-patients-with-acne-vulgaris-100612230",false,"NCT07250880","Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris","CER-S1P-ACNE","Inclusion Criteria:\n\n* For Case Group\n\nThis group will consist of (40) patients :\n\n* Both males and females aged 15-40 years.\n* Mild, Moderate, severe and very severe cases will be included. 5\n\nFor Control Group:\n\n• This group will consist of age- and sex-matched (40) healthy volunteers.\n\nExclusion Criteria:\n\n* Presence of any dermatological condition other than acne vulgaris (for cases).\n\n  * Use of systemic or topical treatment such as isotretinoin or antibiotics within the last 3 months.\n  * Pregnancy or lactation.\n  * History of lipid-lowering therapy or supplements affecting ceramide or sphingolipid metabolism.",true,"ALL","15 Years","40 Years",{"count":39,"type":40},80,"ESTIMATED","OBSERVATIONAL","Acne vulgaris is a common chronic inflammatory skin disorder that affects adolescents and young adults. Recent research has shown that lipid mediators, including ceramides and sphingolipids, play an important role in maintaining skin barrier function and inflammation.\n\nThis study aims to evaluate the serum levels of ceramide C16, ceramide C24, and sphingosine-1-phosphate (S1P) in patients with acne vulgaris and compare them to healthy controls. The goal is to explore their possible role in the pathogenesis and severity of acne. Blood samples will be collected from participants, and quantitative analysis will be performed using liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS).",[44],"Acne Vulgaris","NOT_YET_RECRUITING","2025-11-18",{"date":48,"type":49},"2025-11-26","ACTUAL",{"date":51,"type":40},"2025-11",{"date":53,"type":40},"2026-09",{"name":5,"class":6}]